Gastroenterology
Volume 136, Issue 7 , Pages 2169-2179.e4 , June 2009

Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a

  • Patrick Marcellin

      Affiliations

    • Service d'Hépatologie, U773-CRB3, Hôpital Beaujon, University of Paris, Clichy, France
    • Corresponding Author InformationReprint requests Address requests for reprints to: Prof Patrick Marcellin, Service d'Hépatologie and INSERM U773-CRB3, Hôpital Beaujon, Clichy, France. 100 boulevard du Général Leclerc, 92110 Clichy, France. fax: xxx
    • ,
  • Ferruccio Bonino

      Affiliations

    • Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Policlinico di Milano, Italy
    • ,
  • George K.K. Lau

      Affiliations

    • Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China
    • ,
  • Patrizia Farci

      Affiliations

    • Universita di Cagliari, Cagliari, Italy
    • ,
  • Cihan Yurdaydin

      Affiliations

    • University of Ankara, Faculty of Medicine, Ankara, Turkey
    • ,
  • Teerha Piratvisuth

      Affiliations

    • NKC Institute of Gastroenterology and Hepatology, Department of Internal Medicine, Songklanagarind Hospital, Prince of Songkla University, Hat Yai 90110, Thailand
    • ,
  • Rui Jin

      Affiliations

    • Digestive Department, Beijing You-An Hospital, Beijing, China
    • ,
  • Selim Gurel

      Affiliations

    • Department of Gastroenterology, Uludag University, Bursa, Turkey
    • ,
  • Zhi-Meng Lu

      Affiliations

    • Department of Infectious Diseases, Ruijin Hospital, Shanghai, China
    • ,
  • Jian Wu

      Affiliations

    • Roche, Dee Why, Australia
    • ,
  • Matei Popescu

      Affiliations

    • F. Hoffman-La Roche, Basel, Switzerland
    • ,
  • Stephanos Hadziyannis

      Affiliations

    • Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
    • ,
  • Peginterferon alfa-2a in HBeAg-negative Chronic Hepatitis B Study Group

Received 13 June 2008 ,Accepted 2 March 2009.

References 

  1. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology. 2001;34:617–624
  2. Papatheodoridis GV, Hadziyannis SJ. Diagnosis and management of pre-core mutant chronic hepatitis B. J Viral Hepat. 2001;8:311–321
  3. Funk ML, Rosenberg DM, Lok ASF. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat. 2002;9:52–61
  4. Chu CJ, Keeffe EB, Han SH, et al. Prevalence of HBV precore/core promoter variants in the United States. Hepatology. 2003;38:619–628
  5. EASL International Consensus Conference on Hepatitis B. 13–14 September, 2002 Geneva, Switzerland: consensus statement long version. J Hepatol. 2002;39(Suppl 1):S3–S25
  6. Zarski JP, Marcellin P, Leroy V, et al. Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases. J Hepatol. 2006;45(3):355–360
  7. Santantonio T, Mazzola M, Iacovazzi T, et al. Long-term follow-up of patients with anti-BHe/HBV DNA positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol. 2000;32:300–306
  8. Manesis EK, Hadziyannis SJ. Interferon a treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology. 2001;121:101–109
  9. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131(6):1743–1751
  10. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507–539
  11. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B [published online ahead of print October 29, 2008]. J Hepatol. 2009;50:227–242doi: 10/1016/j.jhep.2008.10.001
  12. Hadziyannis SJ, Papatheodoridis GV, Dimou E, et al. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology. 2000;32:847–851
  13. Liaw YF, Chien RN, Yeh CT, et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology. 1999;30:567–572
  14. Marcellin P, Lau GKK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004;351:1206–1217
  15. Papatheodoridis GV, Manesis E, Hadziyannis S. Long-term follow-up after initial response to interferon therapy in patients with HBeAg-negative chronic hepatitis B [abstract]. Hepatology. 2000;32(Suppl 1):378A
  16. Brunetto MR, Oliveri F, Colombatto P, et al. Treatment of HBeAg-negative chronic hepatitis B with interferon or pegylated interferon. J Hepatol. 2003;39(Suppl 1):S164–S167
  17. Oliveri F, Puoti M, Santantonio T, et al. Impact of IFN on progression of liver disease in hepatitis B “e” antigen (HBeAg) negative chronic hepatitis B (CHB) patients: a long term Italian multicenter A.I.S.F. study. Hepatology. 2005;42(Suppl 1):577A
  18. Ronsin C, Pillet A, Bali C, et al. Evaluation of the COBAS AmpliPrep-Total Nucleic Acid Isolation--COBAS TaqMan hepatitis B virus (HBV) quantitative test and comparison to the VERSANT HBV DNA 3.0 assay. J Clin Microbiol. 2006;44:1390–1399
  19. Chen C-J, Yang H-I, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73
  20. Iloeje UH, Yang HI, Su J, et al. Serum hepatitis B virus DNA level predicts the incidence of liver cirrhosis in persons chronically infected with HBV [abstract]. J Hepatol. 2005;42(Suppl 2):180
  21. Buster EHCJ, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alfa-2b. Gastroenterology. 2008;135:459–467
  22. Brunetto MR, Oliveri F, Coco B, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatology. 2002;36:263–270
  23. Lampertico P, Del Ninno E, Vigano M, et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology. 2003;37:756–763
  24. Lau DT, Everhart J, Kleiner DE, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology. 1997;113:1660–1667
  25. Hadziyannis SJ, Tassopoulos NC, Heathcote J, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med. 2005;352:2673–2681
  26. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354:1011–1020
  27. Marcellin P, Heathcote J, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442–2455
  28. Heathcote E, Gane EJ, deMan RA, et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-positive patients with chronic hepatitis B (study 103), preliminary analysis [abstract]. Hepatology. 2008;48(Suppl 1):158A
  29. Marcellin P, Buti M, Kraztev Z, et al. Two year tenofovir disoproxil fumerate (TDF) and adefovir dipivoxil (ADV) switch data in HBeAg-negative patients with chronic hepatitis B (study 102), preliminary analysis [abstract]. Hepatology. 2008;48(Suppl 1):A146
  30. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol. 2001;34:306–313
  31. Santantonio T, Mazzola M, Iacovazzi T, et al. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol. 2000;32:300–306
  32. van Zonneveld M, Honkoop P, Hansen BE, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology. 2004;39:804–810
  33. Fattovich G, Giustina G, Sanchez-Tapias J, et al. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis (European Concerted Action on Viral Hepatitis (EUROHEP)). Am J Gastroenterol. 1998;93:896–900
  34. Moucari R, Mackiewicz V, Lada O, et al. Early serum HbsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients [published online ahead of print November 19, 2008]. Hepatology. 2009;49:1151–1157doi: 10.1002/hep.22744
  35. Brunetto M, Mouconi F, Bonino F, et al. Hepatitis B virus surface antigen levels–a guide to sustained response to peginterferon alfa-2a in HBeAg-ngative chronic hepatitis. Hepatology. 2009;49:1141–1150
  36. Moucari. HBsAg seroconversion: different kinetics of serum HBsAg level decrease in inactive carriers and chronic hepatitis B patients treated with interferon [abstract 992]. Hepatology. 2007;46(suppl 1):S680A
  37. Perrillo B. Hepatitis B surface antigen quantifications as a current day paradox: obtaining the gold in the face of diminishing returns. Hepatology. 2009;49:1063–1065

 This article has an accompanying continuing medical education activity on page 2388. Learning Objective: Upon completion of this exercise, successful learners will be able to assess the likelihood of sustained response, 3 years post-treatment in patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a, and will be able to utilize this knowledge when assessing the potential treatment options and deciding upon the most appropriate course of management for their patients with chronic hepatitis B.

 Conflicts of interest The authors disclose the following: Dr Marcellin has received consulting and lecture fees from Roche, and grants from Roche, Dr Bonino has received consulting fees from Roche; Dr Lau received consulting fees from Roche, and GlaxoSmithKline, and lecture fees from Roche, and GlaxoSmithKline, Dr Farci has received consulting fees from Roche; Dr Yurdaydin, Dr Piratvisuth, Dr Jin, Dr Gurel, Dr Hadziyannis, and Dr Lu have received grant support from Roche. Mr Wu and Dr Popescu report being employees of Roche.

 Funding Supported by a research grant from F. Hoffmann-La Roche, Basel, Switzerland.

PII: S0016-5085(09)00377-1

doi: 10.1053/j.gastro.2009.03.006

Gastroenterology
Volume 136, Issue 7 , Pages 2169-2179.e4 , June 2009

Article Tools

* Image Usage & Resolution